SEARCH

SEARCH BY CITATION

References

  • 1
    ALLHAT Collaborative group. Major outcomes in highrisk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):29812997.
  • 2
    Cushman WC, Ford CE, Cutler JA, et al. , on behalf of the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393405.
  • 3
    Lenfant C. Commentary: high blood pressure control: put the champagne away. J Clin Hypertens (Greenwich). 2002; 4(6):391392.
  • 4
    Moser M. Comments on ALLHAT and other papers in this issue of the JCH[editorial]. J Clin Hypertens (Greenwich). 2002;4(6):388390.
  • 5
    Moser M. Results of the ALLHAT trial: is the debate about initial antihypertensive drug therapy over [editorial]? J Clin Hypertens (Greenwich). 2003;5(1):58.
  • 6
    Weber M. Commentary: the ALLHAT report: a case of information and misinformation. J Clin Hypertens (Greenwich). 2003;5(1):913.
  • 7
    Wing LM, Reid CM, Ryan P, et al. , on behalf of the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348(7):583592.
  • 8
    Moser M. Is it time for a new approach to the initial treatment of hypertension? Arch Intern Med. 2001;161(9):11401144.